Related Experiment Videos
Congestive heart failure in children
1Pediatric Cardiovascular Program, Duke University Medical Center, Durham, North Carolina, USA.
Insights
Current treatments for heart failure focus on managing symptoms by altering heart function and surgically correcting defects. Future therapies may involve advanced cell and gene treatments for heart disease.
Area of Science:
- Cardiology
- Regenerative Medicine
Background:
- Heart failure treatments aim to reverse negative compensatory mechanisms.
- Myocardial cell regeneration remains a significant challenge.
Purpose of the Study:
- To review current and future therapeutic strategies for congestive heart failure (CHF).
Main Methods:
- Review of medical literature on heart failure management.
- Analysis of pharmacological, surgical, and interventional catheterization approaches.
- Exploration of emerging cellular, subcellular, and gene therapies.
Main Results:
- Pharmacological interventions can reverse deleterious compensatory mechanisms in CHF.
- Surgical and interventional catheterization offer curative or beneficial outcomes for specific defects.
- Cellular, subcellular, and gene therapies represent potential future treatments for CHF and prevention of coronary heart disease (CHD).
Conclusions:
- Current CHF management focuses on optimizing cardiac function and addressing underlying defects.
- Advanced therapies hold promise for simplifying CHF treatment and preventing heart disease.
Abstract:
Although revitalizing dead or severely injured myocardial cells is still beyond the reach of modern treatment, the ability to change the loading conditions and the contractile state of the heart has enabled practitioners to reverse deleterious compensatory mechanisms in patients with CHF. Several new and improved medicines have made this strategy possible. Early and determined surgical treatment of patients with CHF has enabled cure of some previously debilitating or fatal defects. The combined use of surgery and interventional catheterization has allowed many patients to profit from the benefits not available from either modality alone. In the future, cellular, subcellular, and gene therapy may make the treatment of patients with CHF simple and even prevent CHD.